# The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

> **NCT01705509** · NA · TERMINATED · sponsor: **Cardiovascular Institute of the South Clinical Research Corporation** · enrollment: 14 (actual)

## Conditions studied

- Cardiomyopathy

## Interventions

- **DRUG:** Ranolazine

## Key facts

- **NCT ID:** NCT01705509
- **Lead sponsor:** Cardiovascular Institute of the South Clinical Research Corporation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study terminated due to lack of resources.
- **Last updated:** 2020-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01705509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01705509, "The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01705509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*